Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Minute Insight: Best Buy Will Sell Dexcom CGM

Executive Summary

The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.

You may also be interested in...

EY Report Offers Advice For Medtech To Regain Its Pre-COVID Mojo

The medtech industry’s overall revenue growth has slowed down in the last year along with a decline in M&A activity and venture spending in the sector, according to a new report from Ernst & Young. The authors proposed that to overcome those challenges, medtech should invest in a new health care system that is digitized, connected, and intelligent.

Minute Insight: Dexcom Next-Generation G7 CGM Approved In Canada

Dexcom wins Health Canada approval to market its G7 CGM in Canada, following announcements of its ambitious R&D map to expand into metabolic health and new product plans for consumers and the diabetes markets at ADA.

Exec Chat: Dexcom’s CEO On Meeting New CGM Markets While Scoping Consumer Opportunities

In this first of a series of Exec Chats with leaders at major diabetes companies presenting at ADA’s Scientific Sessions 2023, CEO Kevin Sayer discusses Dexcom’s ambitious R&D map to expand into metabolic health and develop innovative new products for diabetes and consumer markets.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts